Market Closed -
Nyse
04:00:00 2024-04-05 pm EDT
|
5-day change
|
1st Jan Change
|
1.1
USD
|
+0.92%
|
|
0.00%
|
+213.84%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
152.5
|
416.6
|
67.39
|
79.71
|
126
|
36.73
|
Enterprise Value (EV)
1 |
178.2
|
508.3
|
153.7
|
158
|
155.2
|
70.99
|
P/E ratio
|
-1.82
x
|
-23.3
x
|
-2.46
x
|
-6.58
x
|
-4.34
x
|
-2.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.97
x
|
4.2
x
|
1.01
x
|
1.06
x
|
1.4
x
|
0.39
x
|
EV / Revenue
|
2.3
x
|
5.12
x
|
2.31
x
|
2.1
x
|
1.72
x
|
0.75
x
|
EV / EBITDA
|
-4.76
x
|
14.9
x
|
750
x
|
17.2
x
|
18.1
x
|
13.3
x
|
EV / FCF
|
-2.97
x
|
-24.1
x
|
35.1
x
|
23.2
x
|
-12.9
x
|
-7.41
x
|
FCF Yield
|
-33.7%
|
-4.15%
|
2.85%
|
4.31%
|
-7.72%
|
-13.5%
|
Price to Book
|
-7.94
x
|
-63.7
x
|
-5.78
x
|
1.9
x
|
2.27
x
|
0.63
x
|
Nbr of stocks (in thousands)
|
21,477
|
22,730
|
23,645
|
46,615
|
84,542
|
104,788
|
Reference price
2 |
7.100
|
18.33
|
2.850
|
1.710
|
1.490
|
0.3505
|
Announcement Date
|
2/19/19
|
3/4/20
|
2/26/21
|
3/1/22
|
3/1/23
|
3/22/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
77.35
|
99.22
|
66.5
|
75.36
|
90.21
|
94.64
|
EBITDA
1 |
-37.41
|
34.15
|
0.205
|
9.191
|
8.597
|
5.335
|
EBIT
1 |
-45.26
|
25.75
|
-8.342
|
1.623
|
0.279
|
-3.573
|
Operating Margin
|
-58.52%
|
25.95%
|
-12.54%
|
2.15%
|
0.31%
|
-3.78%
|
Earnings before Tax (EBT)
1 |
-62.29
|
4.625
|
-27.5
|
-11.37
|
-18.78
|
-13.14
|
Net income
1 |
-79.72
|
-18.63
|
-27.5
|
-11.37
|
-19.88
|
-13.27
|
Net margin
|
-103.07%
|
-18.78%
|
-41.36%
|
-15.09%
|
-22.04%
|
-14.03%
|
EPS
2 |
-3.900
|
-0.7850
|
-1.160
|
-0.2600
|
-0.3435
|
-0.1400
|
Free Cash Flow
1 |
-60.09
|
-21.12
|
4.374
|
6.803
|
-11.99
|
-9.581
|
FCF margin
|
-77.69%
|
-21.28%
|
6.58%
|
9.03%
|
-13.29%
|
-10.12%
|
FCF Conversion (EBITDA)
|
-
|
-
|
2,133.6%
|
74.01%
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/19/19
|
3/4/20
|
2/26/21
|
3/1/22
|
3/1/23
|
3/22/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
25.7
|
91.7
|
86.3
|
78.3
|
29.2
|
34.3
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-0.6878
x
|
2.685
x
|
421.1
x
|
8.52
x
|
3.398
x
|
6.421
x
|
Free Cash Flow
1 |
-60.1
|
-21.1
|
4.37
|
6.8
|
-12
|
-9.58
|
ROE (net income / shareholders' equity)
|
-1,706%
|
-35.3%
|
264%
|
-81.3%
|
-39%
|
-22.4%
|
ROA (Net income/ Total Assets)
|
-16.6%
|
12.1%
|
-4.88%
|
0.77%
|
0.11%
|
-1.44%
|
Assets
1 |
481.5
|
-154
|
564.1
|
-1,478
|
-18,123
|
924.1
|
Book Value Per Share
2 |
-0.8900
|
-0.2900
|
-0.4900
|
0.9000
|
0.6600
|
0.5600
|
Cash Flow per Share
2 |
1.770
|
0.8200
|
0.8300
|
0.5400
|
0.1800
|
0.0800
|
Capex
1 |
10.5
|
8.34
|
7.6
|
5.29
|
8.35
|
8.24
|
Capex / Sales
|
13.61%
|
8.41%
|
11.43%
|
7.02%
|
9.26%
|
8.7%
|
Announcement Date
|
2/19/19
|
3/4/20
|
2/26/21
|
3/1/22
|
3/1/23
|
3/22/24
|
|
1st Jan change
|
Capi.
|
---|
| +213.84% | 116M | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|